Related Experiment Video

Updated: Jun 25, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

The sodium pump alpha1 sub-unit: a disease progression-related target for metastatic melanoma treatment

Véronique Mathieu1, Christine Pirker, Elisabeth Martin de Lassalle

  • 1Laboratory of Toxicology, Institute of Pharmacy, Free University of Brussels, ULB, Brussels, Belgium.

Journal of Cellular and Molecular Medicine
|February 27, 2009
PubMed

Insights

Targeting the alpha1 sodium pump subunit shows promise for melanoma treatment. This subunit is highly expressed in melanoma cells and linked to tumor progression, with cardiotonic steroids demonstrating significant anti-tumor effects.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Melanoma exhibits resistance to apoptosis and high metastatic potential, contributing to poor patient outcomes.
  • Up-regulation of sodium pump alpha subunits is observed in metastatic melanomas.
  • Previous research indicated that inhibiting sodium pump alpha1 subunit activity with cardiotonic steroids reduces melanoma cell migration and induces apoptosis.

Purpose of the Study:

  • To quantify sodium pump alpha subunit expression in melanoma cell lines and clinical samples.
  • To elucidate the role of the alpha1 subunit in melanoma cell biology.
  • To evaluate the anti-tumor efficacy of cardiotonic steroids and alpha1 subunit inhibition in melanoma models.

Main Methods:

  • Quantitative RT-PCR, Western blotting, and immunohistochemistry were employed to assess alpha subunit expression.
  • In vitro cytotoxicity was determined using MTT assays, videomicroscopy, and apoptosis assays.
  • In vivo efficacy was evaluated in a melanoma brain metastasis model using the cardenolide UNBS1450.

Main Results:

  • All tested human melanoma cell lines exhibited high alpha1 subunit expression.
  • A significant correlation between alpha1 subunit expression and the Breslow index was found in 33% of human melanomas.
  • The cardenolide UNBS1450 demonstrated potent in vitro and in vivo anti-tumor activity, reducing cMyc expression and increasing apoptosis.
  • UNBS1450 showed significant efficacy in an aggressive human metastatic brain melanoma model.

Conclusions:

  • The alpha1 sodium pump subunit is highly expressed in melanoma and associated with tumor progression.
  • Targeting the alpha1 sodium pump subunit with agents like UNBS1450 offers a potential therapeutic strategy for melanoma.
  • Further investigation into the alpha1 sodium pump subunit as a novel therapeutic target for melanoma is warranted.

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...